|
Description
The Infectious Disease Research Institute (Seattle, WA) and Chembio Diagnostics, Inc. have entered into two research and development agreements for the development of rapid diagnostic tests for Leishmaniasis and Leprosy, two "neglected diseases" targeted by IDRI. The tests will be developed by Chembio using Chembio's patented Dual Path immunoassay test platform (DPP) and will incorporate IDRI's proprietary antigens.
In preliminary studies conducted during the first quarter of 2007, Chembio demonstrated superior analytical sensitivity on certain well-characterized samples from patients with these diseases. These studies resulted in the decision by Chembio and IDRI to enter into two Cooperative Research and Development Agreements to further their joint efforts.
IDRI, which has funding from the National Institutes of Heath and the Bill and Melinda Gates Foundation... |
More articles from BIOTECH Patent News
Human Genome Sciences and GlaxoSmithKline initiate second phase 3 clin..., May 01, 2007
Martek withdraws original European ARA infant formula patent., May 01, 2007
Oncolytics Biotech announces issuance of 21th United States patent., May 01, 2007
Biomoda files additional patent protection for its lung cancer detecti..., May 01, 2007
NanoLogix files five patents for ultra fast BioNanoChannel diagnostic ..., May 01, 2007
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
